Oxaliplatin(IV) prodrugs, classified by the role of their axial ligands, are presented with a focus on their in vitro stability and activity in in vivo models, illustrating their potential to address current Pt-based chemotherapy's main limitations.
The reduction of Pt(IV) complexes can be monitored by various analytical techniques. These techniques hold significant promise in elucidating the mechanisms of Pt(IV) prodrug activation, aiding in the rational design of novel Pt(IV) prodrugs.
PROTAC–Pt(IV) represents a new class of dual-action Pt(IV) prodrugs integrating platinum drugs with PROTAC-mediated protein degradation, exhibiting superior antitumor efficacy compared to conventional Pt(IV) prodrug and PROTAC alone in vivo.
In this work, a series of novel 6/5/6 tetradentate Pt(II) complexes based on carbazolylpyridine (cp) ligands were designed and synthesized, achieving red emission at 611–624 nm with a quantum efficiency of up to 85% in dichloromethane.
This review explores organic nanodelivery systems in the development of platinum-based anticancer treatments, highlighting benefits, challenges, and potential for groundbreaking therapies.